Does Pennsylvania Medicaid cover Mounjaro?

Quick answer · Type 2 Diabetes

Pennsylvania Medicaid covers Mounjaro for type 2 diabetes with prior authorization on Medicaid.

The card and program names below are mapped to Pennsylvania Medicaid in our records. Coverage depends on the reason for treatment and the requirements in the policy.

Policy last verified June 4, 2026. Policy effective January 1, 2026. Source: mab2025112403.pdf. How we verify this data.

Card and program names on file in Pennsylvania

Select a name to read the Pennsylvania Medicaid policy for Mounjaro. These are names we recognize, including older names and spelling variants; this is not a list of plans currently accepting members.

Don't see your card name? Check your card or call the pharmacy-benefit number on your card. If you also have Medicare, confirm which plan handles this prescription.

Mounjaro for Type 2 Diabetes

Medicaid

Covered with requirements

What you need to qualify

  • Prior trial of another GLP-1 medication (preferred GLP-1 receptor agonists approved for the beneficiary's diabetes diagnosis)

Qualification pathways

You can qualify through any one of these.

Non-preferred GLP-1 for diabetes — Mounjaro initial and renewal

All of:

  • Diagnosis of diabetes
  • The prescribed GLP-1 receptor agonist (Mounjaro/tirzepatide) is FDA-approved for the treatment of diabetes

Plus any one of:

  • History of therapeutic failure of the maximum FDA-approved dose of preferred GLP-1 receptor agonist(s) approved/medically accepted for the beneficiary's diagnosis
  • Contraindication to the maximum FDA-approved dose of preferred GLP-1 receptor agonist(s)
  • Intolerance to the maximum FDA-approved dose of preferred GLP-1 receptor agonist(s) (with chart documentation of troubleshooting over >= 1 month if switching due to intolerance)

Documentation to bring

  • Documentation of diabetes diagnosis
  • Documentation of therapeutic failure of preferred GLP-1(s) at maximum FDA-approved dose, OR contraindication or intolerance (with troubleshooting documentation over >= 1 month if intolerance-based: dietary changes, prescription antiemetics, dose adjustment)
  • Documentation that Mounjaro (tirzepatide) is FDA-approved for the treatment of diabetes
  • Documentation of age-appropriateness per FDA labeling, compendia, or peer-reviewed literature
  • Documentation of no contraindication to Mounjaro
  • If therapeutic duplication: documentation of intent to transition or medical reason for concomitant use

Approval and renewal

  • Initial approval: 12 months
  • Renewal: every 12 months
  • To renew, the plan looks for Renewal requires: (1) diagnosis of diabetes; (2) therapeutic failure of/contraindication to/intolerance to maximum FDA-approved dose of preferred GLP-1(s) for the beneficiary's diagnosis; (3) Mounjaro is FDA-approved for diabetes. No A1C or weight thresholds re-checked at renewal.

Not covered when

  • Overweight/obesity treatment indication excluded
  • Saxenda (liraglutide) not covered for any indication

Policy note: Mounjaro is non-preferred for diabetes on the PA MA PDL. Requires therapeutic failure of, contraindication to, or intolerance to the maximum FDA-approved dose of preferred GLP-1(s) for the beneficiary's diabetes diagnosis. For intolerance-based switching (e.g., from semaglutide to tirzepatide), must document that troubleshooting was tried over at least 1 month: dietary changes (apples, crackers, mint/ginger drinks 30 minutes after dosing), prescription antiemetics, and dose adjustment if lower doses were tolerated. Approval for up to 12 months. Prescriptions limited to 1-month supply per fill.

Policy effective January 1, 2026 · verified June 4, 2026 · source: mab2025112403.pdf

Full Pennsylvania Medicaid coverage page for Mounjaro

Other medications under Pennsylvania Medicaid

All insurance plans · All medications

This page summarizes written Medicaid policies on file. It is not a guarantee of coverage or medical advice. Confirm your current benefits and prior-authorization requirements with your plan.